345 related articles for article (PubMed ID: 17066097)
1. Gene therapy progress and prospects: Duchenne muscular dystrophy.
Foster K; Foster H; Dickson JG
Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
[TBL] [Abstract][Full Text] [Related]
2. Development of therapy for Duchenne muscular dystrophy.
Zhang S; Xie H; Zhou G; Yang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Feb; 21(2):194-203. PubMed ID: 17357471
[TBL] [Abstract][Full Text] [Related]
3. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
4. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
5. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for muscular dystrophy: current progress and future prospects.
Trollet C; Athanasopoulos T; Popplewell L; Malerba A; Dickson G
Expert Opin Biol Ther; 2009 Jul; 9(7):849-66. PubMed ID: 19527108
[TBL] [Abstract][Full Text] [Related]
7. Progress toward gene therapy of Duchenne muscular dystrophy.
Hartigan-O'Connor D; Chamberlain JS
Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
[TBL] [Abstract][Full Text] [Related]
8. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport.
Xiong F; Xiao S; Yu M; Li W; Zheng H; Shang Y; Peng F; Zhao C; Zhou W; Chen H; Fang L; Chamberlain JS; Zhang C
BMC Neurosci; 2007 Jul; 8():50. PubMed ID: 17617925
[TBL] [Abstract][Full Text] [Related]
9. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
[TBL] [Abstract][Full Text] [Related]
10. Full-length dystrophin gene transfer to the mdx mouse in utero.
Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
[TBL] [Abstract][Full Text] [Related]
11. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
13. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
14. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
[TBL] [Abstract][Full Text] [Related]
15. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
Duan D
Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
[TBL] [Abstract][Full Text] [Related]
16. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for muscle disease.
Miyagoe-Suzuki Y; Takeda S
Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
[TBL] [Abstract][Full Text] [Related]
18. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.
Roberts M; Dickson G
Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies for Duchenne and Becker dystrophies.
Voisin V; de la Porte S
Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
[TBL] [Abstract][Full Text] [Related]
20. Gene delivery to dystrophic muscle.
Wells KE; McMahon J; Foster H; Ferrer A; Wells DJ
Methods Mol Biol; 2008; 423():421-31. PubMed ID: 18370219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
